Rocket Pharmaceuticals Inc to Acquire Renovacor, Extending Leadership in AAV-Based Cardiac Gene Therapy Call Transcript - Thomson StreetEvents

Rocket Pharmaceuticals Inc to Acquire Renovacor, Extending Leadership in AAV-Based Cardiac Gene Therapy Call Transcript

Rocket Pharmaceuticals Inc to Acquire Renovacor, Extending Leadership in AAV-Based Cardiac Gene Therapy Call Transcript - Thomson StreetEvents
Rocket Pharmaceuticals Inc to Acquire Renovacor, Extending Leadership in AAV-Based Cardiac Gene Therapy Call Transcript
Published Sep 20, 2022
11 pages (6724 words) — Published Sep 20, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of RCKT.OQ M&A conference call or presentation 20-Sep-22 12:00pm GMT

  
Brief Excerpt:

...Operator Good day, and thank you for standing by. Welcome to the Rocket Pharmaceuticals Business Update Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jessie Yeung, Vice President of IR and Corporate Finance. Please go ahead. Jessie Yeung ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Rocket Pharmaceuticals Inc
Ticker
RCKT.OQ
Time
12:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Tyler Martin Van Buren - Cowen and Company, LLC, Research Division - Analyst : Congratulations on the transaction. I have a couple for you. I guess the first one is the preclinical ejection fraction data is interesting. But do you expect that you'll see the same histologic changes as you've seen with LAMP2B. And then the second question is I believe the severity of the disease is lower than Danon. And so can you speak to the confidence that you have in administering AAV9 to these patients based upon the latest safety data that you've seen from the Danon program?

Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst : Congratulations on deal. Does the acquisition of a cardiomyopathy program with similarities to Danon imply an increased level of confidence in what you may see from the Danon program, just deciding to focus a little bit more in that area. And then how are you thinking going forward about the balance between your AAV and antiviral programs in your pipeline?

Table Of Contents

Rocket Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript – 2023-05-10 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 10-May-23 11:20pm GMT

Rocket Pharmaceuticals Inc at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) Transcript – 2023-04-25 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 25-Apr-23 1:00pm GMT

Rocket Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript – 2023-04-18 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 18-Apr-23 12:45pm GMT

Rocket Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript – 2023-01-09 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 9-Jan-23 10:15pm GMT

Rocket Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript – 2022-09-13 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 13-Sep-22 7:30pm GMT

Rocket Pharmaceuticals Inc, Decibel Therapeutics Inc and Ultragenyx Pharmaceutical Inc at Citi BioPharma Conference- Panel Transcript – 2022-09-07 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 7-Sep-22 3:20pm GMT

Rocket Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript – 2022-05-24 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 24-May-22 11:45am GMT

Rocket Pharmaceuticals Inc at Needham Healthcare Conference Transcript – 2022-04-11 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 11-Apr-22 2:15pm GMT

Rocket Pharmaceuticals Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript – 2022-04-01 – US$ 54.00 – Edited Transcript of RCKT.OQ presentation 1-Apr-22 12:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Rocket Pharmaceuticals Inc to Acquire Renovacor, Extending Leadership in AAV-Based Cardiac Gene Therapy Call Transcript" Sep 20, 2022. Alacra Store. May 02, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/Rocket-Pharmaceuticals-Inc-to-Acquire-Renovacor-Extending-Leadership-in-AAV-Based-Cardiac-Gene-Therapy-Call-T15341698>
  
APA:
Thomson StreetEvents. (2022). Rocket Pharmaceuticals Inc to Acquire Renovacor, Extending Leadership in AAV-Based Cardiac Gene Therapy Call Transcript Sep 20, 2022. New York, NY: Alacra Store. Retrieved May 02, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Rocket-Pharmaceuticals-Inc-to-Acquire-Renovacor-Extending-Leadership-in-AAV-Based-Cardiac-Gene-Therapy-Call-T15341698>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.